CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 243 enrolled
Drug / intervention
Penehyclidine hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04112771
NCT04112771N/ACompleted

Effects of Penehyclidine on Postoperative Nausea and Vomiting in Patients Underging Bimaxillary Surgery: A Retrospective Cohort Study

Peking University First Hospital·observational·Posted Oct 2, 2019·Updated Jun 30, 2020

In Brief

An observational study evaluating Penehyclidine hydrochloride and No penehyclidine hydrochloride for Penehyclidine and 2 related conditions. Completed, enrolled 243 participants across 2 sites.

Detailed Summary

Postoperative nausea and vomiting (PONV) are common complications after surgery. Patients undergoing orthognathic surgery are reported to have a high rate of PONV, especially those undergoing bimaxillary surgery. Activation of cholinergic system plays an important role in the development of PONV. Penehyclidine is an muscarinic antagonists which selectively block M1 and M3 receptors and is commonly used to decrease oral secretion. The purpose of this retrospective cohort study is to investigate whether use of penehyclidine is associated with a reduced risk of PONV in patients undergoing bimaxillary surgery.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedOct 2, 2019
Enrollment StartOct 7, 2019
Primary CompletionDec 30, 2019
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.8 years ago

Interventions

Penehyclidine hydrochloridedrug

Penehyclidine hydrochloride was administered before anesthesia induction.

No penehyclidine hydrochlorideother

Penehyclidine hydrochloride was not administered before anesthesia induction.